SGLT-2 inhibition substantially reduces end-stage kidney disease risk among people with albuminuric diabetic nephropathy [13, 14], and subgroup analyses from one trial suggest there are benefits in certain types of albuminuric non-diabetic causes of CKD [11]. The gene discussed is SLC5A2; the disease is chronic kidney disease.